Liver resection for metastatic melanoma: Equivalent survival for cutaneous and ocular primaries

Journal of Surgical Oncology

Volumn 108, Issue 2, 2013, Pages 129-135

  Ryu, Seung Wook ^a   Saw, Robyn ^a,b   Scolyer, Richard A ^a,b   Crawford, Michael ^a   Thompson, John F ^a,b   Sandroussi, Charbel ^a,c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

liver; melanoma; metastasis; resection; survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CUTANEOUS MELANOMA; EYE CANCER; FEMALE; HUMAN; LIVER METASTASIS; LIVER RESECTION; MALE; METASTATIC MELANOMA; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT OUTCOME;

LIVER; MELANOMA; METASTASIS; RESECTION; SURVIVAL;

ADULT; AGED; EYE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84880310608     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23361     Document Type: Article

References (30)

1. Caralt M, Marti J, Cortes J, et al.: Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. J Hepatobiliary Pancreat Sci 2011; 18: 268-275.
2. Lee ML, Tomsu K, Von Eschen KB:, Duration of survival for disseminated malignant melanoma: Results of a meta-analysis. Melanoma Res 2000; 10: 81-92. (Pubitemid 30127833)
3. Rose DM, Essner R, Hughes TM, et al.: Surgical resection for metastatic melanoma to the liver. Arch Surg 2001; 136: 950-955.
4. Vahrmeijer A, van de Velde C, Hartgrink H, et al.: Treatment of melanoma metastases confined to the liver and future perspectives. Dig Surg 2008; 25: 467-472.
5. Azzola MF, Shaw HM, Thompson JF, et al.: Tumour mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: An analysis of 3661 patients from a single center. Cancer 2003; 97: 1488-1498. (Pubitemid 36297779)
6. Balch CM, Buzaid AC, Soong SJ, et al.: Final version of the American joint committee on cancer staging system for cutaneous melanom. J Clin Oncol 2001; 19: 3635-3648. (Pubitemid 32786276)
7. Pawlik T, Zorzi D, Abdalla E, et al.: Hepatic resection for metastatic melanoma: Distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 2006; 13: 712-720.
8. Sato T:, Locoregional management of hepatic metastases from primary uveal melanoma. Sem Oncol 2010; 37: 127-138.
9. Thompson JF, Soong SJ, Balch CM, et al.: Prognostic significance of mitotic rate in localized primary cutaneous melanoma: An analysis of patients in the multi-institutional American Joint Committee on Cancer on melanoma staging database. J Clin Oncol 2011; 29: 2199-2205.
10. Aoyama T, Mastrangelo MJ, Berd D, et al.: Protracted survival after resection of metastatic uveal melanoma. Cancer 2000; 89: 1561-1568.
11. Patel JK, Didolkar MS, Pickren JW, et al.: Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 1978; 135: 807-810. (Pubitemid 8377329)
12. Mariani P, Piperno-Neumann S, Servois V, et al.: Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol 2009; 35: 1192-1197.
13. Rivoire M, Kodjikian L, Baldo S, et al.: Treatment of liver metastases from uveal melanoma. Ann Surg Oncol 2005; 12: 1-7.
14. Li Y, McClay EF:, Systemic chemotherapy for the treatment of metastatic melanoma. Sem Oncol 2002; 29: 413-426. (Pubitemid 35178281)
15. Adam R, Chiche L, Aloia T, et al.: Hepatic resection for noncolorectal nonendocrine liver metastases. Ann Surg 2006; 244: 524-535.
16. Chua TC, Scolyer RA, Kennedy CW, et al.: Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. Ann Surg Oncol 2012; 19: 1744-1781.
17. Hemming AW, Sielaff TD, Gallinger S, et al.: Hepatic resection of noncolorectal nonneuroendocrine metastases. Liver Transpl 2000; 6: 97-101. (Pubitemid 30123375)
18. Herman P, Machado MA, Montagnini AL, et al.: Selected patients with metastatic melanoma may benefit form liver resection. World J Surg 2007; 31: 171-174. (Pubitemid 46089562)
19. Sanki A, Scolyer RA, Thompson JF:, Surgery for melanoma metastases of the gastrointestinal tract: Indications and results. Eur J Surg Oncol 2009; 35: 313-319.
20. Salmon RJ, Levy C, Plancher C, et al.: Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol 1998; 24: 127-130. (Pubitemid 28205941)
21. Clavien PA, Barkun J, de Oliveira ML, et al.: The Clavien-Dindo classification of surgical complications. Ann Surg 2009; 250: 187-196.
22. Dindo D, Demartines N, Clavien PA:, Classification of surgical complications. A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213. (Pubitemid 38963009)
23. Koch M, Garden J, Padbury R, et al.: Bile leakage after hepatobiliary and pancreatic surgery: A definition and grading of severity by the International Study Group of Liver Surgery. Surgery 2011; 149: 680-688.
24. Frenkel S, Nir I, Hendler K, et al.: Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 2009; 93: 1042-1046.
25. Albert DM, Ryan LM, Borden EC:, Metastatic ocular and cutaneous melanoma: A comparison of patient characteristics and prognosis. Arch Ophthalmol 1996; 114: 107-108. (Pubitemid 26026209)
26. Feldman ED, Pingpank JF, Alexander HR, Jr.:, Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 2004; 11: 290-297. (Pubitemid 40486769)
27. Leiter U, Meier F, Schittek B, et al.: The natural course of cutaneous melanoma. J Surg Oncol 2004; 86: 172-178. (Pubitemid 38880283)
28. Crook TB, Jones OM, John TG, et al.: Hepatic resection for malignant melanoma. Eur J Surg Oncol 2006; 32: 315-317.
29. Flaherty KT, Infante JR, Daud A, et al.: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
30. Hauschild A, Grob JJ, Demidov LV, et al.: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.